Scholar Rock (NASDAQ:SRRK – Get Free Report) and SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Risk and Volatility
Scholar Rock has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Scholar Rock and SAB Biotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scholar Rock | 0 | 0 | 6 | 1 | 3.14 |
| SAB Biotherapeutics | 0 | 0 | 5 | 0 | 3.00 |
Profitability
This table compares Scholar Rock and SAB Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scholar Rock | N/A | -145.60% | -91.83% |
| SAB Biotherapeutics | -1,450.14% | -94.37% | -67.26% |
Institutional and Insider Ownership
91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 19.2% of Scholar Rock shares are held by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Scholar Rock and SAB Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scholar Rock | $33.19 million | 102.53 | -$165.79 million | ($2.35) | -15.47 |
| SAB Biotherapeutics | $2.24 million | 7.05 | -$42.19 million | N/A | N/A |
SAB Biotherapeutics has lower revenue, but higher earnings than Scholar Rock.
Summary
Scholar Rock beats SAB Biotherapeutics on 8 of the 13 factors compared between the two stocks.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.
